|
| 38018226 | Expression analysis of NF1-mutated alleles in a rare compound heterozygous spinal NF1 patient by digital PCR. | Ann Hum Genet | 2024 |
| 36698394 | Assessing the role of sodium fluorescein in peripheral nerve sheath tumors and mimicking lesions surgery: An update after 142 cases. | Front Oncol | 2023 |
| 37820091 | Management of neurofibromatosis type 1 associated tumors of central and peripheral nervous system. | Curr Opin Oncol | 2023 |
| 37217626 | New insights into the molecular basis of spinal neurofibromatosis type 1. | Eur J Hum Genet | 2023 |
| 36445254 | LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL. | Cancer Discov | 2023 |
| 36910634 | Sporadic spinal psammomatous malignant melanotic nerve sheath tumor: A case report and literature review. | Front Oncol | 2023 |
| 34608482 | The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis. | Neuro Oncol | 2022 |
| 36614980 | Towards an Established Intraoperative Oncological Favorable Tool: Results of Fluorescein-Guided Resection from a Monocentric, Prospective Series of 93 Primary Glioblastoma Patients. | J Clin Med | 2022 |
| 36612057 | A Translational Approach to Spinal Neurofibromatosis: Clinical and Molecular Insights from a Wide Italian Cohort. | Cancers (Basel) | 2022 |
| 36077416 | Characterization of 22q12 Microdeletions Causing Position Effect in Rare NF2 Patients with Complex Phenotypes. | Int J Mol Sci | 2022 |
| 34608571 | Mutations associated with hypokalemic periodic paralysis: from hotspot regions to complete analysis of CACNA1S and SCN4A genes. | Neurogenetics | 2022 |
| 32661549 | A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. | Neuro Oncol | 2021 |
| 33601293 | Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. | Eur J Cancer | 2021 |
| 33620087 | MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. | Br J Haematol | 2021 |
| 35008487 | The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors. | Int J Mol Sci | 2021 |
| 34646780 | Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma. | Front Oncol | 2021 |
| 34727807 | Carcinomatosis under control by osimertinib in <i>EGFR</i> and <i>TP53</i> mutated lung adenocarcinoma. | Tumori | 2021 |
| 34388515 | Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). | Eur J Cancer | 2021 |
| 34204877 | Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). | Cancers (Basel) | 2021 |
| 34088874 | Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600-Mutant Adult Glial and Glioneuronal Tumors. | Neurology | 2021 |
| 33140187 | High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. | Cancer Immunol Immunother | 2021 |
| 32609812 | Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2021 |
| 31595648 | Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. | Hum Mutat | 2020 |
| 31724074 | Prospective observational study on the complications and tolerability of a peripherally inserted central catheter (PICC) in neuro-oncological patients. | Support Care Cancer | 2020 |
| 31747009 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2020 |
| 31650436 | In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. | Neurol Sci | 2020 |
| 32575496 | Simultaneous Detection of <i>NF1</i>, <i>SPRED1</i>, <i>LZTR1</i>, and <i>NF2</i> Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. | Genes (Basel) | 2020 |
| 32114667 | Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. | Neurol Sci | 2020 |
| 32413119 | Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions. | Neuro Oncol | 2020 |
| 32518098 | Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. | Clin Cancer Res | 2020 |
| 30471162 | Stroke-like events after brain radiotherapy: a large series with long-term follow-up. | Eur J Neurol | 2019 |
| 31694342 | Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: <i>ANRIL</i> Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients. | Genes (Basel) | 2019 |
| 31744235 | Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. | J Clin Med | 2019 |
| 31771235 | ABCC3 Expressed by CD56<sup>dim</sup> CD16<sup>+</sup> NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. | Int J Mol Sci | 2019 |
| 31766501 | Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort. | Cancers (Basel) | 2019 |
| 32642719 | EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. | Neurooncol Adv | 2019 |
| 32642658 | Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. | Neurooncol Adv | 2019 |
| 31273577 | Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. | J Neurooncol | 2019 |
| 31436563 | Neurological malignancies in neurofibromatosis type 1. | Curr Opin Oncol | 2019 |
| 31392641 | Management of epilepsy in brain tumors. | Neurol Sci | 2019 |
| 31125418 | Defining EGFR amplification status for clinical trial inclusion. | Neuro Oncol | 2019 |
| 30910547 | Biopsy-proven primary angiitis of the central nervous system mimicking leukodystrophy: A case report and review of the literature. | J Clin Neurosci | 2019 |
| 30522967 | Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. | Lancet Oncol | 2019 |
| 30531922 | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Nat Med | 2019 |
| 29290338 | Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. | Am J Hum Genet | 2018 |
| 30105822 | The noncoding RNA AK127244 in 2p16.3 locus: A new susceptibility region for neuropsychiatric disorders. | Am J Med Genet B Neuropsychiatr Genet | 2018 |
| 29632727 | Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8<sup>+</sup> T cell activation in the presence of adjuvant temozolomide. | Oncoimmunology | 2018 |
| 29018053 | Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). | Clin Cancer Res | 2018 |
| 28903444 | Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. | Oncotarget | 2017 |
| 29184769 | Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. | Quant Imaging Med Surg | 2017 |